Update shared on13 Sep 2025
Fair value Increased 1.15%Doximity’s price target was raised modestly to $68.67 as analysts pointed to robust Q1 results, AI-driven strategy enhancements, and conservative guidance as drivers of sustained business momentum.
Analyst Commentary
- Bullish analysts cite strong Q1 results and upwardly revised guidance as evidence of solid business momentum.
- Doximity’s emerging AI strategy, including the launch of AI Scribe and the acquisition of Pathway AI, is seen as reinforcing user engagement and enhancing monetization potential.
- Bullish analysts believe fiscal 2026 guidance is conservative, with growth in the formulary business projected to offset slower growth in other pharma segments, supporting the company's ability to meet or beat outlook targets.
- The company is noted for its attractive business model, generating very high incremental EBITDA margins when revenue exceeds expectations.
- Ongoing stability in pharma client budgets and incremental optimism on AI-driven platform improvements are offset by some lingering macroeconomic caution among more neutral analysts.
What's in the News
- Doximity completed the repurchase of 4,141,229 shares (2.21% of shares outstanding) for $198.32 million under its announced buyback program.
- Management issued guidance for fiscal Q2 revenue of $157–158 million and full-year revenue of $628–636 million ending March 31, 2026.
- Doximity was dropped from multiple Russell value indices, including the Russell 1000 Value, 3000 Value, Midcap Value, 2500 Value, and Small Cap Comp Value indices.
Valuation Changes
Summary of Valuation Changes for Doximity
- The Consensus Analyst Price Target remained effectively unchanged, moving only marginally from $67.89 to $68.67.
- The Future P/E for Doximity remained effectively unchanged, moving only marginally from 57.33x to 57.99x.
- The Discount Rate for Doximity remained effectively unchanged, moving only marginally from 7.81% to 7.82%.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.